CTRI/2023/10/058727
Not yet recruiting
Phase 2
Evaluation of efficacy and safety of polyherbal unani formulation in Nazla Haar (Allergic Rhinitis) - NI
State Unani Medical College Himmatganj Prayagraj0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- State Unani Medical College Himmatganj Prayagraj
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient of any sex
- •2\. Age group between 19 to 50 years
- •3\. Patients clinically diagnosed with Nazla Haar(Allergic Rhinitis).
- •4\. Patients with raised Total Eosinophil Count and Total Serum IgE.
Exclusion Criteria
- •1\. Age below 19 years and above 50 years.
- •2\. Pregnancy and Lactation.
- •3\. Patients with history of Comorbidities like Diabetes and Hypertension, Renal impairment, etc.
- •4\.Patients with other disease of Nose.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Evaluation of efficacy and safety of Polyherbal Unani formulations in the management of EczemaCTRI/2024/02/062979Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital Ayush
Not yet recruiting
Phase 2
Evaluation of efficacy and safety of Polyherbal Unani formulations in the treatment of fungal infection.Health Condition 1: L00-L08- Infections of the skin and subcutaneous tissueHealth Condition 2: L088- Other specified local infections of the skin and subcutaneous tissueCTRI/2024/02/063170Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital
Recruiting
Phase 2
Clinical Study to Evaluate the Effect of Polyherbal Unani formulations in Waram-e-lawzatayn Muzmin (Chronic Tonsillitis).CTRI/2023/09/057524Ministry of Ayush UP
Recruiting
Phase 2
Clinical Study To Evaluate the efficacy of polyherbal Unani formulation in Zukam (Coryza OR Common Cold)CTRI/2023/08/056975State Unani Medical College
Completed
Phase 2
Clinical Trial of Polyherbal Formulation COVI-RB01 As An Add-On Therapy With Standard of Care In Mild And Moderate Covid-19 Positive PatientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2021/10/037378Alakart Bio Pharma Pvt Ltd130